Impact Biomedical (IBO) Receivables (2023 - 2025)

Impact Biomedical (IBO) has reported Receivables for 3 consecutive years, with $5000.0 the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Receivables fell 97.51% year-over-year to $5000.0; the trailing twelve-month figure through Dec 2025 stood at $5000.0 (down 97.51% YoY), and the FY2025 full-year result was $5000.0, down 93.15% from the prior year.
• Receivables retreated to $5000.0 in Q4 2025 per IBO's latest filing, from $199000.0 in the prior quarter.
• Across five years, Receivables topped out at $201000.0 in Q4 2024 and bottomed at $5000.0 in Q4 2025.
• Historically, Receivables has averaged $148625.0 across 3 years, with a median of $163500.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables jumped 57.03% in 2024, then tumbled 97.51% in 2025.
• Over 3 years, Receivables stood at $128000.0 in 2023, then surged by 57.03% to $201000.0 in 2024, then sank by 97.51% to $5000.0 in 2025.
• According to Business Quant data, Receivables over the past three periods registered $5000.0, $199000.0, and $200000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.